HPAPI global market to reach $34.04b in 2026
The global highly potent active pharmaceutical ingredient (HPAPI) market is expected to reach $34.04 billion in 2026, a report has predicted.
List view / Grid view
The global highly potent active pharmaceutical ingredient (HPAPI) market is expected to reach $34.04 billion in 2026, a report has predicted.
The Cell and Gene Therapy Catapult (CGT Catapult) is set to be involved in the establishment of one of the largest life sciences campuses in Europe.
A two-chamber setup (TCS) for containment investigations could predict the dustiness of HPAPIs in a sealed system at different flow conditions.
Virtual seminar presented by Ziva Abraham, President, and CEO of Microrite designed to improve your understanding on current regulatory thinking on designing an effective contamination control strategy.
A new manufacturing facility for sterile injectable drugs has opened in France, housing lines for products such as antibody drug conjugates.
With manufacturing of essential medicines in Europe at risk, Teva’s Phillippe Drechsle looks at the action needed to stop further offshoring to Asia.
1 February 2023 | By ACG Associated Capsules Pvt. Ltd
Watch this webinar on capsule-based dry powder inhalers (cDPI) to discover how capsules work as a unit dosage form for the inhalation-based delivery of the active pharmaceutical ingredients.
30 January 2023 | By Veolia Water Technologies & Solutions, Sievers Instruments
Hear about the latest in microbiological monitoring tools that can help you implement corrective actions in real time.
A first-of-its-kind regulatory framework for point of care manufacturing of innovative medicines is set to be introduced in the UK, ensuring these products are as safe as conventional medicines.
Key stakeholders in the medicine supply chain have been urged by the World Health Organization to take immediate action against recent cases of contaminated medicines.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a UK manufacturing facility good manufacturing practice (GMP) registration for its cannabis API.
Here, microbiology experts Tim Sandle, Tony Cundell and AstraZeneca’s Miriam Guest reflect on key developments in pharmaceutical microbiology during 2022.
To promote Good Manufacturing Practice, Switzerland and the US have signed a Mutual Recognition Agreement to improve pharmaceutical drug inspection.
To support the UK’s investments in manufacturing and R&D, Moderna has joined the Association of the British Pharmaceutical Industry (ABPI).
Adoption of revised general monographs 2034 and 2619 comes after inclusion of a new paragraph approaching N-nitrosamine impurities.